Primary amoebic meningoencephalitis future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
m (Changes made per Mahshid's request)
 
Line 22: Line 22:
[[Category:Inflammations]]
[[Category:Inflammations]]
[[Category:Meningitis]]
[[Category:Meningitis]]
[[Category:Infectious disease]]
 
[[Category:Neurological Disease]]
[[Category:Neurological Disease]]
[[Category:Disease]]
[[Category:Disease]]
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 18:47, 18 September 2017

Primary amoebic meningoencephalitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Primary Amoebic Meningoencephalitis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Primary amoebic meningoencephalitis future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Primary amoebic meningoencephalitis future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Primary amoebic meningoencephalitis future or investigational therapies

CDC on Primary amoebic meningoencephalitis future or investigational therapies

Primary amoebic meningoencephalitis future or investigational therapies in the news

Blogs on Primary amoebic meningoencephalitis future or investigational therapies

Directions to Hospitals Treating Primary amoebic meningoencephalitis

Risk calculators and risk factors for Primary amoebic meningoencephalitis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

Recently, an investigational drug, miltefosine,[1] a breast cancer and anti-leishmania drug, has shown some promise against the free-living amoebae in combination with some other drugs. Miltefosine has shown in vitro and mouse model amebicidal activity against Balamuthia, Naegleria fowleri, and Acanthamoeba.

Future or Investigational Therapies

Miltefosine (oral): The standard miltefosine dosing in adults is as follows:

  • Up to 45 kg body weight: 100 mg daily (i.e., one 50 mg cap po BID, given with food if possible to reduce gastrointestinal side effects)
  • 45 kg body weight and higher: 150 mg daily (i.e., one 50 mg cap po TID, given with food if possible to reduce gastrointestinal side effects )


These standard doses are the maximal tolerated with respect to gastrointestinal symptoms. A higher dose would lead to increased nausea, vomiting, or diarrhea. Miltefosine is mildly nephrotoxic and the dosing might need to be adjusted for patients with impaired kidney function. However, because few data are available about the effective dose for amebic infection, the risk for nephrotoxicity should be balanced with the risk for mortality from PAM. Miltefosine has not been approved by the U.S. Food and Drug Administration (FDA) for use in the U.S. and requires granting of an emergency Investigational New Drug (IND) request from the FDA before being ordered from the manufacturer. CDC is currently working on an expanded access IND protocol which would allow for CDC to acquire and distribute miltefosine for treatment of confirmed cases of Naegleria fowleri infection. Until that protocol is approved, CDC has individual emergency IND request paperwork available upon request that has been pre-filled as much as possible to facilitate clinicians obtaining miltefosine for treatment of PAM and other free-living amoeba infections.

References

  1. Kaminsky R (2002). "Miltefosine Zentaris". Curr Opin Investig Drugs. 3 (4): 550–4. PMID 12090722.

Template:WH Template:WS